Kava para Hyperarousal and Cognitive Insomnia
A Evidências Vários grandes ensaios clínicos mostram de forma consistente benefícios significativos.Based on 23 studies (4 meta-analyses, 1 RCT) with 2,043 total participants. Results are mixed across studies.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'sleepcited.com';
const params = 'ingredient\u003Dkava\u0026condition\u003Dhyperarousal\u002Dinsomnia';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
Conclusão
Based on 23 studies (4 meta-analyses, 1 RCT) with 2,043 total participants. Results are mixed across studies.
Key Study Findings
Case Reports
n=1
6 weeks
Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption.
Dose: None
vs: None
Outcome: acute kava dermopathy with sebaceous gland necrosis
Efeito: None
None
População: 41-year-old Australian woman consuming kava for anxiety and insomnia
Case Reports
n=1
Open-label
Severe kava withdrawal managed with phenobarbital.
Dose: None
vs: None
Outcome: Resolution of kava withdrawal symptoms
Efeito: None
None
População: 45-year-old man with kava and kratom withdrawal
Other
Double-blind
The potential of AB-free kava in enabling tobacco cessation via management of abstinence-related stress and …
Dose: AB-free kava extract
vs: Placebo
Outcome: Tobacco cessation via stress/insomnia management
Efeito: None
None
População: Adult smokers (trial protocol)
Controlled Clinical Trial
Acute oral toxicity, antinociceptive and antimicrobial activities of kava dried extracts and synthetic kavain.
Dose: None
vs: Vehicle control
Outcome: Acute oral toxicity, antinociceptive activity
Efeito: None
None
População: Animal model
Systematic Review
The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review.
Dose: None
vs: None
Outcome: Sleep quality improvement
Efeito: None
None
População: Insomnia patients
Review
Calm Down With Kava: What Clinicians Need to Know.
Dose: None
vs: None
Outcome: None
Efeito: None
None
População: Kava users
Key Statistics
23
Estudos
2043
Participantes
↔
Mixed
A
Nota
Referenced Papers
The Medical journal …
2026
The American journal …
2025
1 citações
BMC complementary medicine …
2024
1 citações
Journal of clinical …
2022
27 citações
Cureus
2022
17 citações
Natural product research
2022
3 citações
Journal of psychosocial …
2022
2 citações
Combinatorial chemistry & …
2021
16 citações
Journal of clinical …
2020
17 citações
Chemical research in …
2019
6 citações
Natural Products from Single Plants as Sleep Aids: A Systematic Review.
Systematic Review
Journal of medicinal …
2018
19 citações
Sleep medicine reviews
2015
152 citações
Holistic nursing practice
2014
10 citações
Toxicokinetics of kava.
Other
Advances in pharmacological …
2011
79 citações
FASEB journal : …
2010
110 citações
Journal of psychopharmacology …
2005
176 citações
Medicine
2005
128 citações
Psychopharmacology
2005
36 citações
Integrative cancer therapies
2004
59 citações
Human psychopharmacology
2003
45 citações
Over-the-counter sleeping pills: a survey of use in Hong Kong and a review of their constituents.
Review
General hospital psychiatry
2002
38 citações
Phytotherapy research : …
2001
74 citações
Human psychopharmacology
2001
52 citações
[Hematogenous contact eczema cause by phytogenic drugs exemplified by kava root extract].
Case Report
Der Hautarzt; Zeitschrift …
1996
22 citações
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Dosagens Comumente Utilizadas
- sleep:
- 120-250 mg kavalactones/day, 1-2 hrs before bed
Limite superior: 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use
Dosagens Estudadas em Pesquisas
| Dosagem | Duração | Efeito | N |
|---|---|---|---|
| None | 6 weeks | Negative | 1 |
| None | -- | Positive | 1 |
| AB-free kava extract | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| not specified | -- | Positive | -- |
Melhor horário: 1-2 hours before bed; avoid daily use beyond 3 months without medical supervision
Safety & Side Effects
Efeitos Colaterais Relatados
- ⚠ Drowsiness and reduced coordination
- ⚠ Hepatotoxicity (rare but serious — consult healthcare provider)
- ⚠ Skin rash (kava dermopathy) with chronic high-dose use
- ⚠ GI discomfort
Interações Conhecidas
- ● Alcohol — increased hepatotoxicity risk and CNS depression
- ● Hepatotoxic medications (acetaminophen, statins) — additive liver stress
- ● Benzodiazepines and sedatives — additive CNS depression
- ● CYP450 substrates (2E1, 1A2, 2D6) — kavalactones may inhibit metabolism
- ● Levodopa and dopaminergic drugs — kava may reduce efficacy
Ingestão máxima tolerável: 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use
Consulte sempre o seu profissional de saúde antes de iniciar qualquer suplemento.Sempre consulte seu profissional de saúde antes de iniciar qualquer suplemento.
Frequently Asked Questions
Does Kava help with Hyperarousal and Cognitive Insomnia?
Based on 23 studies with 2,043 participants, there is strong evidence from multiple clinical trials that Kava may support Hyperarousal and Cognitive Insomnia management. Our evidence grade is A (Strong Evidence).
How much Kava should I take for Hyperarousal and Cognitive Insomnia?
Studies have used various dosages. A commonly studied range is 120-250 mg kavalactones/day, 1-2 hrs before bed. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Kava?
Reported side effects may include Drowsiness and reduced coordination, Hepatotoxicity (rare but serious — consult healthcare provider), Skin rash (kava dermopathy) with chronic high-dose use, GI discomfort. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Kava and Hyperarousal and Cognitive Insomnia?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 23 peer-reviewed studies with 2,043 total participants. The overall direction of effect is mixed.
Related Evidence
Outros ingredientes para Hyperarousal and Cognitive Insomnia
Kava para outras condições
References
- [1] Ali Abid et al.. Med J Aust. 2026. Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption. doi:10.5694/mja2.70120 PubMed
- [2] William Bleifuss et al.. Am J Emerg Med. 2025. Severe kava withdrawal managed with phenobarbital. doi:10.1016/j.ajem.2025.06.016 PubMed
- [3] Chengguo Xing et al.. BMC Complement Med Ther. 2024. The potential of AB-free kava in enabling tobacco cessation via management of abstinence-related stress and insomnia: study protocol for a … doi:10.1186/s12906-024-04722-9 PubMed
- [4] Rita B Soares et al.. J Clin Med. 2022. An Updated Review on the Psychoactive, Toxic and Anticancer Properties of Kava. doi:10.3390/jcm11144039 PubMed
- [5] Kanika Verma et al.. Cureus. 2022. The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review. doi:10.7759/cureus.28425 PubMed
- [6] Juliana Veloso Ferreira et al.. Nat Prod Res. 2022. Acute oral toxicity, antinociceptive and antimicrobial activities of kava dried extracts and synthetic kavain. doi:10.1080/14786419.2021.1973459 PubMed
- [7] Deana Goldin et al.. J Psychosoc Nurs Ment Health Serv. 2022. Calm Down With Kava: What Clinicians Need to Know. doi:10.3928/02793695-20220523-02 PubMed
- [8] Ruhi Ali et al.. Comb Chem High Throughput Screen. 2021. Nutraceuticals for Sleep Disorders. doi:10.2174/1386207324666210121111446 PubMed
- [9] Jennifer L Martin et al.. J Clin Sleep Med. 2020. The Veterans Administration and Department of Defense clinical practice guidelines for the diagnosis and management of sleep disorders: what does … doi:10.5664/jcsm.8486 PubMed
- [10] Pengcheng Wang et al.. Chem Res Toxicol. 2019. Enzymes and Pathways of Kavain Bioactivation and Biotransformation. doi:10.1021/acs.chemrestox.9b00098 PubMed
- [11] Jungyoon Kim et al.. J Med Food. 2018. Natural Products from Single Plants as Sleep Aids: A Systematic Review. doi:10.1089/jmf.2017.4064 PubMed
- [12] Matthew J Leach et al.. Sleep Med Rev. 2015. Herbal medicine for insomnia: A systematic review and meta-analysis. doi:10.1016/j.smrv.2014.12.003 PubMed
- [13] Stephanie Maxine Ross. Holist Nurs Pract. 2014. Psychophytomedicine: an overview of clinical efficacy and phytopharmacology for treatment of depression, anxiety and insomnia. doi:10.1097/HNP.0000000000000040 PubMed
- [14] Anthony Rowe et al.. Adv Pharmacol Sci. 2011. Toxicokinetics of kava. doi:10.1155/2011/326724 PubMed
- [15] Ping Zhou et al.. FASEB J. 2010. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways. doi:10.1096/fj.10-163311 PubMed
- [16] David Wheatley. J Psychopharmacol. 2005. Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. doi:10.1177/0269881105053309 PubMed
- [17] Bradly P Jacobs et al.. Medicine (Baltimore). 2005. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. doi:10.1097/01.md.0000172299.72364.95 PubMed
- [18] Kazuaki Shinomiya et al.. Psychopharmacology (Berl). 2005. Effects of kava-kava extract on the sleep-wake cycle in sleep-disturbed rats. doi:10.1007/s00213-005-2196-4 PubMed
- [19] Keith I Block et al.. Integr Cancer Ther. 2004. Safety and efficacy of herbal sedatives in cancer care. doi:10.1177/1534735404265003 PubMed
- [20] Sheree Cairney et al.. Hum Psychopharmacol. 2003. Saccade and cognitive impairment associated with kava intoxication. doi:10.1002/hup.532 PubMed
- [21] Ka Fai Chung et al.. Gen Hosp Psychiatry. 2002. Over-the-counter sleeping pills: a survey of use in Hong Kong and a review of their constituents. doi:10.1016/s0163-8343(02)00210-4 PubMed
- [22] D Wheatley. Phytother Res. 2001. Kava and valerian in the treatment of stress-induced insomnia. doi:10.1002/ptr.840 PubMed
- [23] David Wheatley. Hum Psychopharmacol. 2001. Stress-induced insomnia treated with kava and valerian: singly and in combination. doi:10.1002/hup.299 PubMed
- [24] R Süss et al.. Hautarzt. 1996. [Hematogenous contact eczema cause by phytogenic drugs exemplified by kava root extract]. doi:10.1007/s001050050451 PubMed
Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.